<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04949880</url>
  </required_header>
  <id_info>
    <org_study_id>ZYLOX34202105</org_study_id>
    <nct_id>NCT04949880</nct_id>
  </id_info>
  <brief_title>A Single-Arm Trail Of Drug-Eluting Balloon Dilatation Catheter Treating Symptomatic Intracranial Atherosclerosis</brief_title>
  <official_title>The Efficacy And Safety Study For Endovascular Treatment Of Symptomatic Intracranial Atherosclerosis Using Drug-Eluting Balloon Dilatation Catheter: An Prospective Multicentre Single-arm Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Zylox Medical Device Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Zylox Medical Device Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a trial designed to test the efficacy and safety of the Drug-Eluting Balloon&#xD;
      Dilatation Catheter.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective multicentre objective performance criteria(OPC) trail conducted by 11&#xD;
      centers in mainland China. Approximately 132 subjects with intracranial atherosclerosis&#xD;
      receive endovascular treatment using the drug-eluting balloon dilatation catheter designed by&#xD;
      Zylox.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Restenosis rate of the target vessel</measure>
    <time_frame>180 days</time_frame>
    <description>Subjects receive Digital Subtraction Angiography(DSA) / Computed Tomography Angiography(CTA) examination in 180 days to analyze whether the degree of stenosis is over 50%, if so, the target vessel restenosis happens.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The average degree of stenosis within the target vessel</measure>
    <time_frame>180 days</time_frame>
    <description>Subjects receive DSA / CTA examination in 180 days, the angiography results are handled by the investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success rate of medical device</measure>
    <time_frame>Intraoperation</time_frame>
    <description>After receiving DSA examination, success rate of medical device is defined as in place-delivery, retracement of balloon after expanding, no fracture or crack, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success rate of surgery</measure>
    <time_frame>Intraoperation</time_frame>
    <description>After receiving DSA examination, success rate of surgery is defined as modified thrombolysis in cerebral infarction score(mTICI) 2b/3 and stenosis&lt;50%,whether assisted treatment is applied or not.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of medical device deficiency</measure>
    <time_frame>Intraoperation</time_frame>
    <description>Medical device deficiency is defined as those risks which may effect the health or safety of subjects under common use, such as misleading label, damaged disinfection packaging, etc.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of stoke</measure>
    <time_frame>7 days / at discharge / 30±7 days / 180±60 days</time_frame>
    <description>The rate of Hemorrhagic stroke as well as symptomatic ischemic stroke.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of death</measure>
    <time_frame>7 days / at discharge / 30±7 days / 180±60 days</time_frame>
    <description>Subjects who died from any cause would be counted.</description>
  </other_outcome>
  <other_outcome>
    <measure>The rate of AE</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The definition of AE(Adverse Event) refers to ISO 14155</description>
  </other_outcome>
  <other_outcome>
    <measure>The rate of SAE</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The definition of SAE (Serious Adverse Event) refers to ISO 14155</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Intracranial Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug-Eluting Balloon Dilatation Catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug-Eluting Balloon Dilatation Catheter</intervention_name>
    <description>The catheter consists of a tip, a drug-coated balloon, a mark, a catheter and a catheter hub. The main component of the drug coating was sirolimus, and the coating was evenly distributed on the effective length surface of the balloon.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 to 80 years;&#xD;
&#xD;
          -  Subject has solitary symptomatic intracranial atherosclerosis that the degree of the&#xD;
             artery stenosis is between 70% and 99% diagnosed by angiography；&#xD;
&#xD;
          -  The target artery locates in Vertebral Artery(VA), Internal Carotid Artery(ICA),&#xD;
             Middle Cerebral Artery(MCA) or Basilar Artery(BA);&#xD;
&#xD;
          -  Subject has at least two atherosclerosis risk factors including diabetes, history or&#xD;
             present hypertension, hyperlipidemia, smoking, age&gt;45；&#xD;
&#xD;
          -  Modified Rankin Scale(mRS) score≤2 before enrollment;&#xD;
&#xD;
          -  Subject or legal representative is able to understand the purpose of study, agrees to&#xD;
             to provide follow-up data and has provided written informed consent;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of severe ischemic stroke within 2 weeks；&#xD;
&#xD;
          -  History of intracranial hemorrhage(including intraparenchymal hemorrhage, massive&#xD;
             subarachnoid hemorrhage, subdural hemorrhage and epidural hemorrhage) within 3 months;&#xD;
&#xD;
          -  Hypertension uncontrolled by medicine(Systolic pressure≥180 mmHg or diastolic&#xD;
             pressure≥110mmHg continuously);&#xD;
&#xD;
          -  Associated intracranial arteriovenous malformation, aneurysms or tumors;&#xD;
&#xD;
          -  The length of the target vessel&gt;10mm and acute angle&gt;90°;&#xD;
&#xD;
          -  History of stent intervention within the target vessel;&#xD;
&#xD;
          -  Allergic to heparin, sirolimus, contrast agents, aspirin, clopidogrel, anesthetics；&#xD;
&#xD;
          -  History of gastrointestinal hemorrhage within 6 months before providing informed&#xD;
             consent or unable to receive antiplatelet therapy；&#xD;
&#xD;
          -  Platelet(PLT)&lt;90*10^9/L;&#xD;
&#xD;
          -  Creatinine&gt;250umol/L;&#xD;
&#xD;
          -  International Normalized Ratio(INR)&gt;1.5;&#xD;
&#xD;
          -  Expected life &lt;12 months;&#xD;
&#xD;
          -  Female subjects who are pregnant, having a pregnancy plan, or lactating within the&#xD;
             study period;&#xD;
&#xD;
          -  Unable to cooperate with or tolerate the interventional surgery;&#xD;
&#xD;
          -  Subjects who have participated in other clinical investigations or haven't reach the&#xD;
             primary end point;&#xD;
&#xD;
          -  Intracranial artery stenosis caused by arterial dissection, arteritis, and thrombosis;&#xD;
&#xD;
          -  Unsuitable tortuous artery for delivery, deployment and retrieval of the device;&#xD;
&#xD;
          -  The degree of stenosis within the non-responsibility vessels&gt;70%;&#xD;
&#xD;
          -  Other circumstances judged by researchers that are not suitable for enrollment;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianmin Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changhai Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liqun Jiao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xuanwu Hospital, Beijing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Liang</last_name>
    <phone>13819565660</phone>
    <email>jie.liang@zyloxmedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of USTC</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wannan Medical College</name>
      <address>
        <city>Wuhu</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cangzhou People's hospital</name>
      <address>
        <city>Cangzhou</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Hospital Of Traditional Chinese And Western Medicine</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Northen Theater Command</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linyi People's Hospital</name>
      <address>
        <city>Linyi</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Chao-Yang hospital, Capital medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xuanwu Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital of Shanghai</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2021</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Arteriosclerosis</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

